[go: up one dir, main page]

EP1450816A4 - METHOD FOR TREATING DISORDER IN CONNECTION WITH INCREASED CHOLESTERITE CONCENTRATION - Google Patents

METHOD FOR TREATING DISORDER IN CONNECTION WITH INCREASED CHOLESTERITE CONCENTRATION

Info

Publication number
EP1450816A4
EP1450816A4 EP02802882A EP02802882A EP1450816A4 EP 1450816 A4 EP1450816 A4 EP 1450816A4 EP 02802882 A EP02802882 A EP 02802882A EP 02802882 A EP02802882 A EP 02802882A EP 1450816 A4 EP1450816 A4 EP 1450816A4
Authority
EP
European Patent Office
Prior art keywords
cholesterite
concentration
increased
connection
treating disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02802882A
Other languages
German (de)
French (fr)
Other versions
EP1450816A2 (en
Inventor
Shutsung Liao
Ching Song
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago filed Critical University of Chicago
Publication of EP1450816A2 publication Critical patent/EP1450816A2/en
Publication of EP1450816A4 publication Critical patent/EP1450816A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
EP02802882A 2001-11-08 2002-11-08 METHOD FOR TREATING DISORDER IN CONNECTION WITH INCREASED CHOLESTERITE CONCENTRATION Withdrawn EP1450816A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34802001P 2001-11-08 2001-11-08
US348020P 2001-11-08
PCT/US2002/035900 WO2003039480A2 (en) 2001-11-08 2002-11-08 Method of treating disorder related to high cholesterol concentration

Publications (2)

Publication Number Publication Date
EP1450816A2 EP1450816A2 (en) 2004-09-01
EP1450816A4 true EP1450816A4 (en) 2008-02-13

Family

ID=23366328

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02802882A Withdrawn EP1450816A4 (en) 2001-11-08 2002-11-08 METHOD FOR TREATING DISORDER IN CONNECTION WITH INCREASED CHOLESTERITE CONCENTRATION

Country Status (5)

Country Link
EP (1) EP1450816A4 (en)
JP (1) JP2005508368A (en)
CA (1) CA2466033A1 (en)
TW (1) TW200300078A (en)
WO (1) WO2003039480A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078396B2 (en) 2001-05-03 2006-07-18 Arch Development Corporation Method of treating disorder related to high cholesterol concentration
US8399441B2 (en) 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
WO2006046593A1 (en) 2004-10-27 2006-05-04 Daiichi Sankyo Company, Limited Benzene compound having 2 or more substituents
US7902240B2 (en) 2006-11-13 2011-03-08 Novartis Ag Substituted pyrazole and triazole compounds as KSP inhibitors
EP2459581A4 (en) 2009-07-29 2012-12-26 Univ Chicago LIVER X RECEPTOR AGONISTS
US9034859B2 (en) 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
CN107936076B (en) * 2011-09-08 2021-10-15 萨奇治疗股份有限公司 Neuroactive steroids, compositions, and uses thereof
LT3932932T (en) 2013-03-13 2025-09-10 Sage Therapeutics, Inc. NEUROACTIVE STEROIDS AND THEIR USES
HK1220472A1 (en) * 2013-03-13 2017-05-05 萨奇治疗股份有限公司 Neuroactive steroids, compositions, and uses thereof
JP2016193835A (en) * 2013-09-04 2016-11-17 学校法人常翔学園 Nuclear receptor liver X receptor agonist
MX2021011641A (en) 2013-12-24 2023-03-10 Durect Corp Uses of oxygenated cholesterol sulfates (ocs).
WO2015195967A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2017007832A1 (en) 2015-07-06 2017-01-12 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
HUE053778T2 (en) 2015-07-06 2021-07-28 Sage Therapeutics Inc Oxysterols and methods of use thereof
LT3812392T (en) 2015-07-06 2025-08-11 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US20190330259A1 (en) 2016-04-01 2019-10-31 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
SMT202100468T1 (en) 2016-07-07 2021-09-14 Sage Therapeutics Inc 11-substituted 24-hydroxysterols for use in the treatment of nmda related conditions
EP4101861A1 (en) 2016-08-02 2022-12-14 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
BR112019006365A2 (en) 2016-09-30 2019-08-06 Sage Therapeutics Inc c7 substituted oxisterols and methods of use thereof
IL297804A (en) 2016-10-18 2022-12-01 Sage Therapeutics Inc Oxysterols and methods of use thereof
IL293231B1 (en) 2016-10-18 2025-06-01 Sage Therapeutics Inc Oxysterols and methods of using them
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1405818A (en) * 1972-12-06 1975-09-10 Shionogi & Co 6beta-amino-steroids and the preparation thereof
WO1994002503A1 (en) * 1992-07-22 1994-02-03 Enosys S.A. Bile acid derivative and use thereof in therapy
WO2000066611A1 (en) * 1999-04-30 2000-11-09 Arch Development Corporation Steroid derivatives
WO2002090375A2 (en) * 2001-05-03 2002-11-14 The University Of Chicago Liver x receptor agonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3963765A (en) * 1973-04-01 1976-06-15 Yehuda Mazur Preparation of derivatives of cholesterol
US4217288A (en) * 1977-03-24 1980-08-12 Wisconsin Alumni Research Foundation Anti-vitamin D compounds
JPS61254599A (en) * 1985-05-07 1986-11-12 Sumitomo Pharmaceut Co Ltd Fluorine derivative of cholesterol
IL105050A0 (en) * 1992-03-27 1993-07-08 Lilly Co Eli Steroid derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1405818A (en) * 1972-12-06 1975-09-10 Shionogi & Co 6beta-amino-steroids and the preparation thereof
WO1994002503A1 (en) * 1992-07-22 1994-02-03 Enosys S.A. Bile acid derivative and use thereof in therapy
WO2000066611A1 (en) * 1999-04-30 2000-11-09 Arch Development Corporation Steroid derivatives
WO2002090375A2 (en) * 2001-05-03 2002-11-14 The University Of Chicago Liver x receptor agonists

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
LAFFITTE B A ET AL: "LXRS CONTROL LIPID-INDUCIBLE EXPRESSION OF THE APOLIPOPROTEIN E GENE IN MACROPHAGES AND ADIPOCYTES", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 98, no. 2, 16 January 2001 (2001-01-16), pages 507 - 512, XP001097136, ISSN: 0027-8424 *
SONG C ET AL: "EFFECTS OF SELECTIVE LIVER X RECEPTOR AGONIST ON ATHEROSCLEROSIS PROGRESSION AND REGRESSION OF APOE KNOCK-OUT MICE", CIRCULATION, AMERICAN HEART ASSOCIATION, DALLAS, TX, US, vol. 104, no. 17, 23 October 2001 (2001-10-23), pages II329, XP009016063, ISSN: 0009-7322 *
SONG C ET AL: "Hypolipidemic effects of selective liver X receptor alpha agonists", STEROIDS, BUTTERWORTH-HEINEMANN, STONEHAM, MA, US, vol. 66, no. 9, September 2001 (2001-09-01), pages 673 - 681, XP004304415, ISSN: 0039-128X *
SONG C ET AL: "SELECTIVE ACTIVATION OF LIVER X RECEPTOR ALPHA BY 6ALPHA-HYDROXY BILE ACIDS AND ANALOGS", STEROIDS, ELSEVIER SCIENCE PUBLISHERS, NEW YORK, NY, US, vol. 65, no. 8, 2000, pages 423 - 427, XP000952749, ISSN: 0039-128X *
SPARKS D L ET AL: "Link between heart disease, cholesterol, and Alzheimer's disease: a review.", MICROSCOPY RESEARCH AND TECHNIQUE 15 AUG 2000, vol. 50, no. 4, 15 August 2000 (2000-08-15), pages 287 - 290, XP002462914, ISSN: 1059-910X *

Also Published As

Publication number Publication date
WO2003039480A3 (en) 2003-06-19
TW200300078A (en) 2003-05-16
JP2005508368A (en) 2005-03-31
CA2466033A1 (en) 2003-05-15
WO2003039480A2 (en) 2003-05-15
EP1450816A2 (en) 2004-09-01

Similar Documents

Publication Publication Date Title
EP1450816A4 (en) METHOD FOR TREATING DISORDER IN CONNECTION WITH INCREASED CHOLESTERITE CONCENTRATION
DE60215241D1 (en) Method and device for reducing interference in decoded images with postfiltering
DE60120520D1 (en) METHOD FOR TREATING WASTEWATER
DE60122532D1 (en) METHOD FOR TREATING SEVERAL BORROOCH INTERVALS
DE60233415D1 (en) DEVICE AND METHOD FOR PRODUCING CARBONATED SOUR WATER AND CARBONATED WATER
DE60103174D1 (en) METHOD FOR PREVENTING OR REDUCING THE TURBIDITY IN BEVERAGES
DE69903332D1 (en) METHOD FOR DEPLOYING THE METALION CONCENTRATION IN SALT SOLUTIONS
EP1589990A4 (en) METHOD FOR TREATING CANCER IN HUMANS
DE60106854D1 (en) Method and device for the electrodeionization of water
DE60206052D1 (en) SYSTEM AND METHOD FOR PROCESSING FLIGHTLAND
DE60102016D1 (en) METHOD FOR TREATING MOTION DISORDERS
DE60017188D1 (en) PROCESS FOR IMPLEMENTING SYNTHESEGAS IN HIGHER HYDROCARBONS
DE60210199D1 (en) Method for determining type groups in pictures
DE60104188D1 (en) METHOD AND DEVICE FOR TREATING WATER / WASTEWATER
DE60104156D1 (en) Device and method for purifying water
ATE227644T1 (en) METHOD AND DEVICE FOR PREVENTING SMALL LEAKES IN THE ZONE LAMINATE
ATE296915T1 (en) METHOD FOR TEXTILE TREATMENT
DE60304649D1 (en) Method and device for reducing false contours in digital displays with pulse-number modulation
DE60302319D1 (en) System and method for purifying water
DE69915390D1 (en) DEVICE AND METHOD FOR ULTRAVIOLET TREATING FLUIDS
DE602004010381D1 (en) METHOD AND DEVICE FOR TREATING WATER FOR INJECTION DRILLING
DE69907349D1 (en) Process for reducing stress in GaN devices
DE69919421D1 (en) Method and device for treating food with ozone
EP1635801A4 (en) METHOD FOR TREATING AND PREVENTING CARDIAC ARTHYTHMIA
ATE374799T1 (en) METHOD FOR TREATING PIGMENTS IN PARTICULAR FORM

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040604

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SONG, CHING

Inventor name: LIAO, SHUTSUNG

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/28 20060101ALI20071219BHEP

Ipc: A61P 9/10 20060101ALI20071219BHEP

Ipc: A61P 3/06 20060101ALI20071219BHEP

Ipc: A61K 31/575 20060101AFI20071219BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20080114

17Q First examination report despatched

Effective date: 20090206

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090818